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Cardiorespiratory fitness 
assessment using risk‑stratified 
exercise testing and dose–response 
relationships with disease 
outcomes
Tomas I. Gonzales1, Kate Westgate1, Tessa Strain1, Stefanie Hollidge1, Justin Jeon1,2, 
Dirk L. Christensen1,3, Jorgen Jensen1,4, Nicholas J. Wareham1 & Søren Brage1*
Cardiorespiratory fitness (CRF) is associated with mortality and cardiovascular disease, but assessing 
CRF in the population is challenging. Here we develop and validate a novel framework to estimate 
CRF (as maximal oxygen consumption,  VO2max) from heart rate response to low‑risk personalised 
exercise tests. We apply the method to examine associations between CRF and health outcomes in 
the UK Biobank study, one of the world’s largest and most inclusive studies of CRF, showing that 
risk of all‑cause mortality is 8% lower (95%CI 5–11%, 2670 deaths among 79,981 participants) and 
cardiovascular mortality is 9% lower (95%CI 4–14%, 854 deaths) per 1‑metabolic equivalent difference 
in CRF. Associations obtained with the novel validated CRF estimation method are stronger than those 
obtained using previous methodology, suggesting previous methods may have underestimated the 
importance of fitness for human health.
Maximal oxygen consumption  (VO2max) is the gold-standard measure of cardiorespiratory fitness (CRF) and 
a powerful predictor of all-cause and cause-specific  mortality1–3 and  morbidity4–7.  VO2max is rarely directly 
measured in population studies due to cost and safety concerns. Alternative methods have been developed to 
indirectly measure  VO2max from heart rate (HR) response to incremental submaximal exercise  tests8. Screening 
procedures are generally used to exclude high-risk individuals from CRF testing, causing selection bias. Ironi-
cally, excluded individuals are more likely to experience incident disease events, making it harder to examine 
relationships between measured CRF and disease outcomes.
Exercise tests typically used in population studies are broadly classified as steady-state tests or ramped tests. 
Steady-state tests consist of several stepwise work rate (WR) increments every 4–6 min, allowing HR and  VO2 to 
stabilise at each WR. Methods for estimating  VO2max from submaximal HR response to steady-state testing are 
well-studied and  validated9. Steady-state testing can be long and inefficient, however, depending on the number of 
WR increments and impractical for populations with low exercise  tolerance10. Ramped tests continuously increase 
WR in small increments. This allows HR and  VO2 response to be characterised over a wider range of WR values 
in less time and enables the rate at which WR is increased (i.e. ramp rate) to be individualised to the participant’s 
ability and contraindications to exercise. Ramped tests present an analytic challenge: at a given ramped WR, HR 
and  VO2 values will be less than those measured during a steady-state test at an equivalent  WR11. Thus,  VO2max 
estimates from ramped tests may be biased if the HR- or  VO2-ramp response is extrapolated from submaximal 
to maximal levels using methods validated for steady-state tests. Alternative methods for estimating  VO2max 
from HR- or  VO2-ramp response may be valid for common ramp rates but are insufficient for tests individualised 
across a wide range of ramp  rates12–14.
We designed a ramped submaximal cycle ergometer test to assess CRF in 80,000 participants from the UK 
Biobank (UKB) study. The UKB-CRF test had relatively low WR and was individualised depending on presumed 
ability and a preliminary health risk assessment, resulting in 11 sets of protocols for men and women (22 in 
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total). Previous attempts at estimating  VO2max from UKB-CRF test data have assumed no difference in estima-
tion bias between different test protocols, and some use only a small proportion of available test  data15–21. These 
approaches may broadly rank individuals by CRF level, but external data are required to verify their internal 
validity and establish absolute validity against directly measured  VO2max.
Here we develop and validate a novel CRF estimation method for the UKB-CRF test using exercise test data 
from a validation study of participants, age-, sex- and BMI-matched to the UKB sample. We first devise a hierar-
chical CRF estimation framework using ramped and steady-state HR response features to estimate  VO2max. We 
then demonstrate the validity of  VO2max estimates against direct measurements, apply the framework to estimate 
CRF in UKB participants, and conduct survival analyses to examine associations between CRF and prospective 
health outcomes. Finally, we compare our findings with previous methods used to estimate CRF in UKB.
Results
Development and validation of CRF estimation method for the UKB‑CRF test. We recruited 
105 female (mean age: 54.3y ± 7.3) and 86 male (mean age: 55.0y ± 6.5) validation study participants (Supple-
mental Fig. 1). Participants completed a series of UKB-CRF tests and a submaximal steady-state test to charac-
terise exercise HR response across different test protocols.  VO2max was directly measured during an independ-
ent maximal exercise test (Fig. 1A). All participants contributed submaximal exercise test data. Some maximal 
exercise test data were excluded due to missing HR and  VO2 response data (n = 25) and failure to achieve pre-
defined maximal exercise threshold criteria (n = 33). Participant characteristics were generally similar in these 
subsamples.
HR response features derived from the UKB-CRF test vary with ramp rate of the assigned protocol and, if 
unaccounted for, will result in biased CRF estimates (Fig. 1B). HR response features may also be of poor quality 
or missing, a common situation in exercise testing. We addressed these issues by integrating UKB-CRF test and 
steady-state test HR response features (Fig. 1C–E) into a multilevel CRF estimation framework (Supplemental 
Table 1). The framework uses these features to estimate the HR–WR relationship that would be established if a 
longer steady-state test had been completed instead of the short ramped UKB-CRF test. Maximal WR is then 
estimated by extrapolation to age-predicted maximal HR (HRmax). This framework approach minimises bias 
introduced by protocol assignment of ramp rate. It also enables the application of different estimation models to 
different data availability scenarios. We derived several estimation models, notated as M1 through M5 in order 
of comprehensiveness. The highest-level model (M1) used more HR response features to estimate CRF, while 
lower-level models (M2 through M5) used fewer.
An accepted method for estimating  VO2max from submaximal cycle ergometry is to estimate maximal steady-
state WR from HR response and convert the estimated maximal steady-state WR to  VO2max using the American 
College of Sports Medicine (ACSM) metabolic equation for  cycling9. Before applying this equation, we verified 
that maximal WR estimated from the UKB-CRF test by the multilevel framework corresponded to maximal 
steady-state WR by comparing WR estimates with WR measured at the respiratory compensation point (RCP) 
from the maximal exercise test. The WR at RCP is equivalent to maximal steady-state WR and is the WR above 
which anaerobic metabolism is needed to sustain exercise until exhaustion. Figure 2 shows agreement with WR 
at RCP using the most comprehensive model for each test type (M1: ramp tests; M4: flat tests). Agreement for 
remaining estimation models is shown in Supplemental Table 2. Across estimation models (M1 through M5), 
estimated WR were strongly correlated with WR at RCP (Pearson’s r range 0.81–0.86) with no significant mean 
bias (Bias range in women: − 3.7 to 3.8 W; in men: − 5.2 to 0.1 W). Mean bias also did not differ between low and 
high ramped tests, but root-mean-square error was generally lower for flat tests. Correlations were higher when 
WR was computed using features from ramp- and recovery-phase data (models M1 through M3) compared to 
using only flat-phase data (models M4 and M5), although all models were relatively precise. We also compared 
estimated WR with WR measured at the lactate threshold (Supplemental Table 3) and WR measured at  VO2max 
(Supplemental Table 4).
After confirming that WR computed from the multilevel framework corresponded to WR at RCP, we esti-
mated  VO2max by applying the ACSM metabolic equation. We then compared these  VO2max estimates with 
 VO2max directly measured from the maximal exercise test. Figure 3 demonstrates  VO2max agreement using the 
most comprehensive estimation model for each test type (M1: ramp tests; M4: flat test). Agreement for remain-
ing estimation models is shown in Supplemental Table 5. Estimated  VO2max was correlated with measured 
 VO2max (Pearson’s r range 0.68–0.74) with no significant mean bias (Bias range in women: − 0.8 to 0.4 ml  O2 
 kg−1  min−1; in men: − 0.3 to 0.3 ml  O2  kg−1  min−1), establishing the multilevel framework’s absolute validity. We 
also quantified the proportion of bias emerging from uncertainty when using age-predicted versus measured 
HRmax in the multilevel framework (Supplemental Table 6); agreement improved only slightly when using meas-
ured HRmax. As a sensitivity analysis, we also evaluated agreement between estimated and directly measured 
 VO2max in all participants with usable maximal test data and relaxing the criteria for maximal effort (n = 178). 
Estimated and directly measured  VO2max were not statistically significantly different across all comparisons 
in this analysis.
We next addressed whether the multilevel framework would yield similar CRF estimates from different UKB-
CRF test protocols completed by the same validation study participant (i.e. internal validity). Within-participant, 
we compared  VO2max estimates from low and high ramp tests across estimation models M1–M3 and M5, as well 
as between flat tests across M4 and M5 (Supplemental Table 7).  VO2max estimates from different UKB-CRF test 
protocols were highly correlated across estimation models (Pearson’s r range: 0.91–0.99). While mean bias was 
minimal across all comparisons (Bias range: − 0.6 to 0.0 ml  O2  kg−1  min−1), some were statistically significantly 
different from zero mean bias. We also examined differential bias by protocol ramp rate (from 0 W  min−1 for flat 
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tests and 7.5–25 W  min−1 for ramp tests), finding mean bias to be minimal across all ramp rates tested (Fig. 3, 
lower panel).
For method-comparison purposes, we also assessed the absolute and internal validity of a simple linear 
regression CRF estimation method used previously by our group and a two-point CRF estimation method used 
by other groups working with UKB data. These latter two methods relate exercise HR response to WR without 
accounting for protocol ramp rate. Both methods demonstrated overestimation bias and low precision when 
applied to ramped tests but had low bias when applied to flat tests (Supplemental Fig. 2).
To assess measurement consistency of the UKB-CRF test, we evaluated short-term test–retest reliability in 
validation study participants and long-term test–retest reliability in UKB participants (Fig. 4). In validation 
study participants with short-term repeat tests (within 2 weeks, n = 87), estimated  VO2max values from the first 
and second UKB-CRF tests were highly correlated (r = 0.91) with no mean difference. Agreement was nearly 
as strong (λ = 0.79) in UKB participants with long-term repeat tests (about 2.8 years between tests, n = 2877).
Figure 1.  Conceptual framework and design for validation study. (A) Overview of the five exercise tests 
performed by validation study participants (3 UKB-CRF tests (flat protocol, low ramp protocol, high ramp 
protocol), 1 steady-state test unique to the validation study, and 1 maximal exercise test to measure  VO2max). 
X-axes: Time; Y-axes: Work rate (WR). Tests were completed consecutively, and work rates were individualised 
according to standardised criteria (See `Experimental procedure and equipment’ in Methods). UKB-CRF test 
and steady-state test data were used for method development. Maximal exercise test data were withheld from 
method development and used for validation purposes only. (B) Conceptual plot of WR-to-VO2 response 
during steady-state and ramped exercise tests.  VO2 increases linearly at a rate proportional to the rate of change 
in WR (i.e. ramp rate) until  VO2max is reached (in an exhaustive test). The WR-to-  VO2 relationship (line slope) 
changes depending on the ramp rate of the test. As ramp rate decreases, the WR when  VO2max is achieved 
approaches the maximal WR for an exhaustive steady-state test. Note that  VO2 is extrapolated to maximal values 
for demonstrative purposes, but in the validation study ramped and steady-states tests were non-exhaustive. 
(C) Exemplar HR data (blue scatter and grey line; upper panel), WR data (red line; lower panel), and test phase 
annotation for ramp test. (D,E) Feature extraction for ramp phase using simple linear regression model and for 
recovery phase using first-order exponential decay model (see Supplemental Methods).
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Application of  VO2max estimation method in UKB cohort. After establishing the absolute validity, 
internal validity, and test–retest reliability of the multilevel framework for interpreting UKB-CRF test data, we 
applied the framework to estimate CRF in UKB (Supplemental Fig. 3 and Supplemental Table 8) and examined 
prospective associations with health outcomes. In total, 42,351 women and 37,650 men from UKB were consid-
ered in this analysis. Baseline participant characteristics are shown by sex-specific and age-adjusted CRF tertiles, 
across half-decade age groups, in Supplemental Table 9. Estimated  VO2max was higher in men compared to 
women, and in younger versus older adults. Participants in the middle and higher CRF tertiles also had better 
baseline measures of heart and lung function, lower body weight, and better self-perceived health than partici-
pants in the lower tertile.
To examine associations between CRF and prospective health outcomes in UKB, we used Cox proportional 
hazards regression to estimate hazard ratios per 1-metabolic equivalent difference in CRF (METs; 1 MET = 3.5 ml 
 O2  kg−1  min−1) for fatal and nonfatal events, excluding those experiencing the event in question in the first 
2 years of follow-up. In total, 2670 participants died during a median 9.9 years (interquartile range 9.7–10.0) of 
follow-up (746,377 person-years). After adjustment for potential confounders, each 1-MET difference in CRF 
was associated with approximately 8% (95%CI 5–11%) lower all-cause mortality (Fig. 5); this equates to a dif-
ference in mortality of about 23% between top and bottom CRF tertiles. Associations were stronger for deaths 
from respiratory disease (RD; 14% lower per 1-MET, 95%CI 8–19%) and similar for deaths from cardiovascular 
disease (CVD; 9%, 95%CI 4–14%), and cancers (8%, 95%CI 5–12%). Higher CRF was more strongly associated 
with lower mortality risk in obese compared to non-obese participants (Supplemental Fig. 4).
Analyses of incident disease outcomes combined fatal and non-fatal events from hospital admissions data 
over 6.9 (interquartile range 6.7–7.0) years of follow-up. Risk of chronic obstructive pulmonary disease (COPD; 
10% lower per 1-MET, 95%CI 4–16%) and heart-failure (11%, 95%CI 3–19%) were more strongly associated 
with CRF than stroke (3%, 95%CI − 5 to 10%), ischaemic heart disease (IHD; 2%, 95%CI − 2 to 5%), and atrial 
fibrillation (AF; − 7%, 95%CI − 1 to − 12%). Associations with CRF were not significant in obese participants 
for these endpoints (Supplemental Fig. 4).
For method comparison purposes, associations were also examined for CRF computed using the simple linear 
regression CRF estimation method. Associations were generally shallower and estimated with less uncertainty 
using simple linear regression, an analysis which also included fewer participants compared to the analysis using 
the multilevel framework.
We used cubic spline regression to examine natural variation and potential nonlinearity in dose–response 
associations between CRF and prospective health outcomes (Fig. 6; obesity-stratified result in Supplemental 
Fig. 5). For method comparison purposes, separate sets of dose–response curves were modeled for CRF when 
computed with the multilevel framework and when using the simple linear regression method. For mortality 
outcomes, CRF was inversely associated with death from all causes, CVD, RD, and cancer in the CRF range of 
3–11 METs. Relationships were steeper at the low end of that range and shallower at higher CRF levels. The 
shape of estimated CRF dose–response relationships varied considerably across incident disease outcomes. In 
Figure 2.  Scatterplots (top row) and Bland–Altman plots (bottom row) demonstrating agreement between 
work rates measured at the respiratory compensation point (RCP) and work rates estimated from flat ramp 
tests (left column), low ramp tests (middle column), and high ramp tests (right column) using the most 
comprehensive prediction equation from the multilevel framework (M1 for ramp tests; M4 for flat test). r: 
Pearson’s correlation coefficient, rho: Spearman’s rank correlation coefficient. RMSE: Root-mean-square error.
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the range of 3–8 METs, CRF was inversely associated with incidence of IHD, heart-failure, AF, stroke, and COPD, 
but disease associations flattened (IHD, heart failure, COPD) or became positive (AF, stroke) above 8 METs. 
Differences between these associations and those observed using the simple linear regression to estimate CRF 
were most evident at the tails of the distributions.
We performed several sensitivity analyses to determine whether health associations with CRF computed 
from the multilevel framework were altered by restricting the analytical sample or by using different estima-
tion models in the multilevel framework to compute CRF. Compared to the main analysis, health associations 
with CRF were slightly weaker but estimated dose–response curves were qualitatively similar when the analytic 
sample was restricted so as to be matched with the sample used when the simple linear regression method was 
applied (Supplemental Figs. 6 and 7). To examine differences in health associations by estimation models in the 
multilevel framework, we split the analytic sample into two separate sets of analyses for those who either per-
formed a ramp test (Supplemental Figs. 8 and 9) or a flat test (Supplemental Fig. 10). In the ramp test analysis, 
associations were generally stronger using more comprehensive estimation models (M1–3) compared to less 
comprehensive models (M5). Estimated dose–response curves were qualitatively similar for all outcomes. The 
association with incident AF, however, was a positive monotonic relationship at all estimation models in the 
ramp test subsample (event rate 217 per 100,000 person-years), rather than the U-shaped relationship found in 
the main analysis. In the subsample allocated a flat test (Supplemental Fig. 10), the association with incident AF 
was positive, non-significant, and at a higher event rate (460 per 100,000 person-years). The analysis in the flat 
test subsample is primarily a comparison of associations for CRF estimated by M4 and M5. Associations were 
generally similar between the two estimation models but non-significant due to the small sample size. We did 
not estimate dose–response curves in the flat test subsample for the same reason.
Figure 3.  Scatterplots (top row) and Bland–Altman plots (second row) demonstrating agreement between 
directly measured  VO2max and  VO2max estimated from flat tests (left column), low ramp tests (middle 
column), and high ramp tests (right column) using the most comprehensive equation from the multilevel 
framework (M1 for ramp tests; M4 for flat test). Below these (bottom row), the box plot demonstrates agreement 
across all ramp rates tested using estimates from the multilevel framework, the simple linear regression method, 
and the two-point estimation method. r: Pearson’s correlation coefficient, rho: Spearman’s rank correlation 
coefficient. RMSE: Root-mean-square error.
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Discussion
We have developed a novel multilevel CRF estimation method based on HR response to short, individualised 
submaximal exercise tests and applied it in one of the largest and most inclusive population-based studies of CRF. 
We establish the validity and reliability of this new method in an independent validation study and demonstrate 
advantages over other methods applied in previous population studies.
The multilevel framework method estimates  VO2max by modeling maximal steady-state exercise capacity 
from HR response to the UKB-CRF test. This approach minimises CRF estimation bias that may be introduced 
by the UKB-CRF test individualisation process. We demonstrate that for each 1-MET difference in CRF estimated 
using the multilevel method, all-cause mortality was 8% lower and CVD mortality was 9% lower; associations 
nearly twice as strong as those estimated when using a method that did not use external data to map between 
ramped and steady-state  exercise15. Improvements in CRF estimation validity and disease outcome characterisa-
tion may have broad implications for future research in UKB.
We have reported on a range of associations between CRF and prospective health outcomes in UKB, dem-
onstrating the protective effects of CRF on all-cause and cause-specific mortality and morbidity. Our findings 
are largely in agreement with numerous other populations-based  studies1–3, however associations between CRF 
and non-fatal incidence rates of IHD, stroke, and AF were not significant. In previous work, dose–response 
associations were J-shaped for  stroke22 and U-shaped for  AF23. Another study with longer follow-up time and 
more incident events reported inverse relationships between CRF and  AF24. As for cancer mortality, we found 
an inverse relationship between CRF and all-cancer mortality, in agreement with previous  studies25,26. Addi-
tional follow-up time is warranted to investigate CRF associations with site-specific cancers in UKB. Additional 
follow-up would, however, also increase the probability that participants may change their CRF level over time, 
which would dilute observed associations between a single baseline measure of CRF and health outcomes. The 
Cox proportional hazards model estimates the difference in hazards of the outcome in question by baseline 
Figure 4.  Scatterplots (top row) and Bland–Altman plots (bottom row) demonstrating short- and long-term 
test–retest reliability. r: Pearson’s correlation coefficient, rho: Spearman’s rank correlation coefficient. RMSE: 
Root-mean-square error. Lamda: Regression-dilution coefficient. SE: Standard error. Short-term reliability data 
are from the validation study (n = 87, follow-up ~ 10 days) and long-term reliability data are from the repeat-
measures sub-study in UK Biobank (n = 2877, follow-up ~ 2.8 years).
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exposure level, and if this exposure level is very stable over time, the estimated association will be a more accurate 
reflection of the importance of that exposure than if it were more variable. We show in this work that CRF has a 
long-term reliability of around 0.80, indicating good stability. However, if we were to formally apply correction 
for the element of instability using regression dilution bias methods, the point estimate of hazard ratios would 
be about 20% stronger than what we report here but with wider confidence intervals.
We have developed a novel multilevel estimation framework that optimises the validity of  VO2max estimates 
from the UKB-CRF test. The key strengths of the framework are that it: (1) uses HR response features across all 
test phases to infer the relationship between HR and exercise intensity; (2) is flexible to the availability or absence 
of HR response features due to data quality issues; and (3) harmonises the inferential modeling of HR response 
features to the within-person invariant relationship between steady-state HR and exercise intensity. For these 
reasons, predicted CRF values and health associations we have presented diverge from previous reports of CRF 
in UKB. In a previous  analysis15, we estimated CRF by using simple linear regression to establish the relationship 
between ramp test HR response and WR. This approach is currently the most common in the field but does not 
account for the protocol individualisation process of ramp rates used in UKB. Using external validation data, we 
show that this approach overestimates  VO2max differentially by test protocol, thus limiting the ability to validly 
compare  VO2max estimates from different UKB-CRF tests. Lacking protocol comparison data, previous work 
could only partially address the impact of this by a meta-analytic approach. Our new approach resolves this issue 
at the individual level and demonstrates stronger associations with all-cause and cause-specific mortality and 
morbidity compared to this previous non-validated method. We can have more confidence in these associations 
because validity of the exposure is now documented.
Figure 5.  Hazard ratio and 95% confidence interval (CI) for prospective log-linear associations (Cox 
regression) between fatal and non-fatal outcomes in the UK Biobank with cardiorespiratory fitness in metabolic 
equivalents (METs, per 3.5 ml  O2·kg−1  min−1) computed from the multilevel framework and simple linear 
regression methods. Event-rate per 100,000 person-years. AF: atrial fibrillation; COPD: chronic obstructive 
pulmonary disease; CVD: cardiovascular disease; IHD: ischaemic heart disease; RD: respiratory disease. COPD 
incidence mostly reflects severe COPD since only ~ 25% of cases end up in hospital. Mortality and incidence 
event-rates differ between fitness prediction methods owing to different inclusion criteria at the estimation level.
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Other approaches also use simple linear regression, but establish the relationship between HR and exercise 
capacity by relating resting HR to only a single measurement of HR during the  test16,17,19–21,27–30. HR measure-
ment noise will greatly decrease precision of this approach, and resulting CRF estimates are still subject to bias 
that will differ by protocol ramp rate. Another reported  approach18,31–33 is to use the maximally achieved WR to 
infer CRF. As most participants completed their test, this approach merely reflects the protocol that participants 
were assigned according to age, sex, body size, resting HR, and exertional chest pain risk, with the latter feature 
most indicative of test risk-stratification. While prospective associations of such an exposure measure with CVD 
endpoints do to a degree validate the stratification of risk, it is not possible to interpret these results solely as 
associations with CRF. At best, it is a composite score of exercise capacity and cardiac risk.
Our CRF estimation approach may also have implications for exercise prescription in clinical environments. 
CRF testing in UKB has demonstrated that it is safe to obtain valid  VO2max estimates in a population setting 
while including some individuals with contraindications to exercise. In practice, such individuals would be pre-
scribed a less strenuous exercise test that could contain less information about their physiological state compared 
to a more strenuous test. The multilevel framework approach we describe in this work for interpreting such test 
results yields unbiased estimates of CRF, addressing a well-recognised limitation of exercise  testing34. Future 
research is warranted to investigate whether the multilevel framework can be generalised to other ramp-style 
exercise tests.
The strengths of our study include independent validation work for our  VO2max estimation approach prior 
to estimating dose–response relationships with disease outcomes in the UK Biobank. There are also some limita-
tions. The exercise capacity of validation study participants was slightly higher than the average capacity of UKB 
participants. Furthermore, the comparatively relaxed testing conditions in the validation study may not directly 
match those in UKB, where testing was conducted in large testing centres and where a variety of additional expo-
sures were examined under stringent time constraints. We also did not directly evaluate the validity of UKB-CRF 
test protocols with ramp rates at 2.5 and 5.0 W  min−1. Agreement for ramp rates above and below these untested 
rates were unbiased, however. Finally, we examined non-fatal health outcomes using only hospitalisation data; 
this does not necessarily capture all disease events in a given category.
Conclusions
We have demonstrated the absolute validity, internal validity, and test–retest reliability of a novel  VO2max 
estimation method for individualised ramped exercise tests that can be safely and efficiently applied in popu-
lation studies. Our analytic approach uses a generalised multilevel modeling framework that bridges the gap 
between steady-state and ramped incremental exercise, addressing a persistent problem in exercise physiology 
Figure 6.  Hazard ratio and 95% confidence interval (CI) for nonlinear associations (cubic splines, Cox 
regression) between fatal and non-fatal outcomes in the UK Biobank with cardiorespiratory fitness in metabolic 
equivalents (METs, per 3.5 ml  O2·kg−1·min−1) computed from the multilevel framework and simple linear 
regression methods. Hazard ratios were computed relative to a fitness reference point of 8.0 METs. AF: atrial 
fibrillation; COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; IHD: ischaemic heart 
disease; RD: respiratory disease. Mortality and incidence counts (superimposed histograms) differ between 
fitness estimation methods owing to different inclusion criteria at the estimation level.
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and prescription. CRF estimated in this way is more strongly associated with mortality and other disease end-
points than previous methodology, strengthening the case for promoting CRF in the general population.
Methods
UKB‑CRF test description. The UKB-CRF test protocol design and individualisation process are described 
in detail by the most recent test  manual35. Briefly, participants were categorised into separate risk levels accord-
ing to questions adapted from the Rose-Angina questionnaire. Participants with “minimal” and “small” risk 
completed an individualised ramp test, those with “medium” risk completed a flat test, and those with “high” risk 
did not complete an exercise test. Ramped tests began with a 2-min flat-phase at a single WR (30 W for females, 
40 W for males) followed by a 4-min ramp-phase where WR increased continuously to a pre-specified target 
WR. The target WR was calculated as a risk-adjusted percentage (50% for those with “minimal” risk, 35% for 
“small” risk) of the maximal WR predicted from an equation derived from maximal exercise (cycle ergometer) 
testing data collected in the Danish Health Examination Survey 2007–200836. The computed value for target 
WR was combined with participant sex (“F” for female, “M” for male) to notate different exercise protocols. For 
example, a male participant with “minimal” risk and predicted WR at  VO2max of ~ 200 W would have a target 
work rate of 100 W and be individualised to UKB protocol “M100”. Flat tests consisted of a single 6-min flat-
phase. Participants cycled at a 60-rpm cadence while WR and heart rate (HR) were monitored. All tests ended 
with a 1-min recovery-phase where participants sat quietly and motionless on the ergometer. No adverse events 
were reported when this test was applied in UKB.
Validation of UKB‑CRF test. Validation study participants. We recruited a subsample of participants 
from the Fenland study, a population-based study in Cambridgeshire,  UK37, using an age-, sex- and BMI-strat-
ified random sampling procedure (Supplemental Table 10). Exclusion criteria were: heart pacemaker; unable 
to walk without aid; history of angina pectoris; blood pressure greater than 180/110 mm Hg; musculoskeletal 
injury that would impair cycling on the ergometer; pregnancy; and currently taking cardioactive drugs (e.g. 
beta-blockers, aspirin). Ethical approval was obtained by the University of Cambridge Human Biology Research 
Ethics Committee (Ref: HBREC/2015.16). All participants provided written informed consent.
Experimental procedure and equipment. Validation study participants were screened according to standardised 
procedures used for the UKB-CRF  test35. Then, participants completed the UKB flat test, two UKB ramped tests 
at different ramp rates, a steady-state test (unique to the validation study), and another ramped test (validation 
only) to elicit  VO2max (Fig. 1A). Tests were conducted consecutively, separated by at least 15 min of rest, and 
were specified according to the test that the participant would have been assigned had they been part of UKB 
(see Supplemental Table 11). The target (highest) WR for the second ramped test was at least 30 W greater than 
the first; thus, each participant completed a “low” and “high” ramped UKB test. The steady-state test consisted of 
four incremental 4-min flat-phases with each WR increment ranging from 10 to 20 W. For the ramped max test, 
participants were fitted with a face mask to measure respiratory ventilation and gas exchange and cycled while 
WR increased until exhaustion.  VO2max was considered reached if two of the following criteria were met: a res-
piratory exchange ratio exceeding 1.20; no  VO2 increase despite increasing WR (< 2.5 ml  O2  kg−1  min−2); and no 
HR increase despite increasing WR. During data analysis, the levelling-off criterion was confirmed by inspecting 
whether the first differential of HR and  VO2 data approached zero over the last 1-min period of the maximal test.
VO2max was expressed as the average of the two highest  VO2 measurements in the last forty-five seconds of 
the maximal exercise test. WR values were measured at  VO2max (i.e. maximal work rate achieved on the test, 
WRmax), at the lactate threshold (LT), and at the respiratory compensation point (RCP). The work rate at LT was 
measured at the point when both ventilatory equivalent of oxygen  (VE/VO2) and end-tidal pressure of oxygen 
 (PETO2) increased with no increase in ventilatory equivalent of carbon dioxide  (VE/VCO2). The work rate at RCP 
was measured at the point when both  VE/VO2 and  VE/VCO2 increased and end-tidal pressure of carbon dioxide 
 (PETCO2) decreased (see Supplemental Fig. 11)38. Directly measured WR at LT and RCP were determined visually 
by three independent investigators, blinded to all other measures except the variables above needed for making 
direct measurements. The median value among investigators was considered the final value.
Cycling was performed on an electromagnetically-braked stationary bike (eBike ergometer, GE) while elec-
trocardiography (ECG) was recorded using 4-lead ECG (Cardiosoft) on the forearms and a Actiwave Cardio 
device (CamNtech, Papworth, UK) on the chest with sampling frequency of 128 Hz. The 4-lead ECG leads were 
placed on the cubital fossa and ventral wrist of the left and right arms (mimicking the UKB protocol). Cycling 
WR were controlled by computer software. Respiratory gas measurements were conducted using a computerised 
metabolic system with Hans Rudolph face masks (Oxycon Pro, Erich Jaeger GmbH, Hoechberg, Germany) as 
validated  elsewhere39.
All ECG signals were processed using the Physionet Toolkit implementation of the SQRS  algorithm40, which 
applies a digital filter to the measured ECG and identifies the downward slopes of the QRS  complexes41. The 
resulting inter-beat-intervals were converted to beats-per-minute values using the “ihr” package in the PhysioNet 
Toolkit, as described  previously15. Pulmonary gas exchange data were sampled breath-by-breath. All data were 
linearly interpolated to derive quasi-continuous HR response and respiratory measures at 1 s time resolution. 
Sections of linearly interpolated HR data greater than 1 s in duration were removed prior to analysis.
CRF estimation framework: conceptual and modeling framework. Our approach for estimating  VO2max from 
UKB-CRF test HR response is illustrated in Fig. 1B–E. Here we first describe a  VO2max estimation method for 
HR response to steady-state exercise. We then adapt this method to the UKB-CRF test by using a multilevel 
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hierarchical framework of linear models to harmonise HR response features extracted from flat and ramped 
UKB-CRF tests to those extracted from steady-state exercise.
Conceptual framework. VO2max can be estimated from HR response to exercise at steady-state WR incre-
ments using linear extrapolation of the submaximal HR-to-WR  relationship42. For this approach, an individual 
exercises at two or more submaximal WR increments while HR is recorded. The steady-state HR response at 
each test increment is then regressed against WR to establish a line-of-best fit for the observed HR-to-WR rela-
tionship (W  bpm−1). This relationship can be represented as:
where WRt and HRt are paired measurements at several test increments, β1ss is the linear regression slope repre-
senting the steady-state HR-to-WR relationship, and β0ss is the intercept of that regression. The regression line is 
extrapolated to age-predicted maximal HR (HRmax)43 to estimate the maximal steady-state WR that would be 
achieved if the exercise test was completed to exhaustion.  VO2max is then estimated by converting the extrapo-
lated maximal steady-state WR value to net  VO2 using a caloric equivalent of oxygen and adding an estimate of 
resting  VO2 plus the  VO2 required for unloaded  cycling44.
The HR-to-WR linear extrapolation approach presents challenges when applied to ramped exercise HR 
response. Assuming HR and  VO2 responses are linearly related, the principal methodological issues  are45–47: (1) 
within-participant, the  VO2-to-WR relationship and total time delay for  VO2 response to achieve linearity after 
ramped exercise onset will vary across ramped tests as a function of ramp rate; (2) The ramped  VO2-to-WR 
relationship decreases asymptotically with ramp rate and, as ramp rate approaches zero, becomes similar to 
values determined from steady-state exercise; (3) the  VO2-to-WR relationship has high test–retest variability; 
and (4) the  VO2-to-WR relationship diverges from linearity above RCP. Thus, the HR-to-WR linear extrapola-
tion approach will induce  VO2max overestimation bias as a function of ramp rate, demonstrate low test–retest 
reliability, and have poor precision if the WR computed at age-predicted HRmax is greater than the WR at RCP.
Modeling framework. We addressed these methodological issues by constructing a multilevel CRF estimation 
framework that computes a participant’s steady-state HR-to-WR relationship using features extracted from HR 
response to flat or ramp UKB-CRF test protocols. The framework was derived using a three-stage hierarchical 
linear model. The first stage equates WR computed from steady-state test HR response (Eq. 1) with WR com-
puted from dynamic regression coefficients that vary between and within individual participants as a function 
of lower-stage hierarchical features. Within every ith individual participant, each having completed a set of p 
exercise protocols:
Stage-1 (base-stage equating steady-state test HR response with UKB-CRF flat and ramped HR response):
where (1) β0p[ss]i and β1p[ss]i are linear regression coefficients estimated from the steady-state protocol (p[ss]); 
(2) HRtp[ss]i is a sequence of t simulated steady-state HR values, equally spaced and spanning the submaximal 
intensity range; (3) WRtp[ss]i is a sequence of t steady-state WR values computed with β0p[ss]i , β1p[ss]i , and HRtp[ss]i 
(thus, a matrix representation of the line defined by Eq. 1); and (4) β0p[UKB]i and β1p[UKB]i are dynamic regression 
coefficients that, while unique to each UKB protocol (p[UKB]) and individual, converge to the values of β0p[ss]i 
and β1p[ss]i by their linkage with WRtp[ss]i . β0p[UKB]i and β1p[UKB]i are estimated at the second stage using combina-
tions of HR-response and protocol-based features:
Stage-2 (HR-response and protocol features extracted from flat and ramped UKB-CRF tests):
where (1) γ0xi and γ1xi are sets of a fixed regression coefficients for HR-response and protocol-level features 
Pxp[UKB]i ; and (2) γ00i and γ10i are the mean intercept and slope for the ith individual participant. γ00i and γ10i are 
estimated at the third stage:
Stage-3 (pretest participant characteristics):
where (1) δ00x and δ10x are sets of b fixed regression coefficients for participant characteristics Ixi ; and (2) δ000 
and δ100 are the model-invariant intercept and slope. β0p[UKB]i and β1p[UKB]i can be estimated using different sets 
of HR-response and protocol features (Pxp[UKB]i ) as well as different sets of participant characteristics (Ixi ) . We 
leveraged this adaptability to derive five WR estimation models (notated as M1–M5; Supplemental Table 1), each 
using different combinations of HR response feature sets, so that our approach was robust to different data quality 
(1)β0ss + β1ss · HRt = WRt
(2)β0p[ss]i + β1p[ss]i ·HRtp[ss]i = WRtp[ss]i = β0p[UKB]i + β1p[UKB]i · HRtp[ss]i
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scenarios encountered when analysing HR response data in UKB. Additional details regarding the extraction of 
feature sets included in Pxp[UKB]i and Ixi are provided in Supplemental Methods.
Application of multilevel framework. VO2max was estimated from the multilevel framework by extrapolating 
the linear fit defined by β0p[UKB]i and β1p[UKB]i  to age-predicted  HRmax43 and converting the resultant maxi-
mal steady-state WR value to  VO2max using the American College of Sports Medicine metabolic equation for 
 cycling9. We also estimated WR and  VO2max values using a simple linear regression  approach15, a two-point 
estimation  method19, and an approach for steady-state  tests15 (see ‘Prediction of VO2max using alternative 
methods’ in Supplemental Materials).
Agreement analyses. We used Bland–Altman  analysis48 to quantify agreement between estimated WR and 
 VO2max values with those directly measured during the maximal exercise test. Correlations between estimated 
and directly measured values were quantified using Pearson’s r and Spearman’s rho. One-sample t-tests were 
performed to determine whether mean biases were statistically significantly different from zero mean bias. Esti-
mation model precision was expressed as the root mean square error (RMSE) between estimated and directly 
measured values. ANOVA repeated measures were used to test differences between estimated and directly meas-
ured values across estimation models.
Short‑term test–retest reliability. To assess short-term test–retest reliability, a subsample of 87 validation study 
participants completed a second UKB-CRF test within 2 weeks after main testing, identical to either the low or 
high ramped test at the main visit. Estimated  VO2max values from first and second tests were compared using 
agreement analysis.
Estimation of  VO2max and associations with prospective health outcomes in UKB. UKB par‑
ticipants. The UKB is a prospective cohort study of 502,625 older adults. Baseline data collection was con-
ducted between 2006 and 2010 where a variety of physical measurements, biological samples, and health ques-
tionnaires were administered; repeat-measures visits were conducted between 2012 and 2013. The UKB-CRF 
test was offered approximately 100,000 times (last 79,209 participants from baseline and 20,218 from the repeat-
measures visit). The study was approved by the North West Multicentre Research Ethics Committee and partici-
pants provided written informed consent.
Implementation of CRF estimation in UKB. VO2max values were estimated in UKB participants, largely as 
described above for the validation study. Supplemental Fig. 12 describes specific criteria used to assign the mul-
tilevel framework estimation models for the primary analysis. Age-predicted HRmax was reduced by 20 beats-
per-minute in those taking beta-blockers49.
Long‑term test–retest reliability of CRF. To assess long-term test–retest reliability, we compared estimated 
 VO2max values at baseline and the first follow-up test in those UKB participants with repeat tests (n = 2877, 
mean follow-up time 2.8 years). The follow-up UKB-CRF test protocol was re-individualised at the time of test-
ing and therefore may have differed from the baseline protocol.
Health characteristics across CRF levels in UKB. Health characteristics were described across age-adjusted and 
sex-specific CRF  categories50. We age-stratified the UKB cohort in half-decades as < 50, 50–54, 55–59, 60–64, 
and ≥ 65 years, defined CRF categories by tertiles (“lower”, “middle”, and “higher”) of estimated  VO2max levels 
from each age group, and combined CRF categories from each age group to form CRF categories for the entire 
UKB cohort. Health characteristics were compared across CRF tertiles for men and women separately.
Survival analyses. Cox regression with age as the underlying timescale was used to estimate log-linear associa-
tions between estimated  VO2max levels (in METs; 1 MET = 3.5 ml  O2  kg−1  min−1) and mortality and incident 
disease outcomes. We compared prospective associations between two  VO2max estimation approaches: the mul-
tilevel framework developed in this study and the previously described method using simple linear regression. 
Vital status and hospital episodes of UKB participants were established by linkage to national registry data 
obtained from the Health and Social Care Information Centre (now NHS Digital) for England and Wales and 
the Information Services Department (ISD) for Scotland. The censoring date for mortality outcomes was 31st 
March 2020. Censoring dates for incident disease outcomes were 31st January 2018 in England and Wales, and 
30th November 2016 in Scotland. International Classification of Diseases (ICD) 10th edition (ICD-10) codes 
were used to define health outcomes; heart failure (I50, I11.0, I13.0, I13.2), stroke (I60-166), ischaemic heart dis-
ease (IHD; I20-I25), atrial fibrillation (AF; I48), and chronic obstructive pulmonary disease (COPD; J44). Fatal 
outcomes were all-cause mortality, cardiovascular disease mortality (CVD; I5-I9, I10-I89), respiratory disease 
mortality (RD; J00-J99), and cancer mortality (C00-97 and D00-D49).
Models were adjusted for age, sex, body weight, ethnicity, smoking status, employment status, Townsend 
index of deprivation, alcohol consumption, red meat intake, medication use (beta blockers, calcium channel 
blockers, ACE inhibitors, diuretics, bronchodialators, lipid-lowering agents, iron deficiency agents), hyperten-
sion, diabetes, and pre-baseline self-report and hospital episodes of cancer. When analysing fatal outcomes, 
models were additionally adjusted for pre-baseline self-report and hospital episodes of heart failure, IHD, stroke, 
AF, and COPD. When analysing specific incident disease outcomes (combined non-fatal and fatal), however, 
participants were excluded if these pre-baseline events were reported. Potential residual confounding by obesity 
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was addressed in stratified analyses. Participants experiencing disease events in the first two years of follow-up 
were excluded (analysis specific). Nonlinear associations between estimated  VO2max levels and each of the 
health outcomes were evaluated using a cubic spline regression model with three knots placed at the 25th, 50th, 
and 75th percentiles of the  VO2max distribution. Spline models were adjusted using all covariates listed above; 
these models were used to estimate dose–response curves for the association between CRF and hazard ratios of 
the disease outcomes, using 8.0 METs as the reference exposure point.
This study complied with the items listed in the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines. All methods were performed in accordance with relevant guidelines and 
regulations including the Declarations of Helsinki.
Statistical software. All analyses were performed in Stata/SE 15.1 (StataCorp, Texas, USA). Statistical 
significance was set at p < 0.05.
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